Perspective Therapeutics (CATX) stock plunges 22% as Phase 1/2a trial results for VMT-α-NET radiopharmaceutical therapy disappoint investors
https://seekingalpha.com/news/4316690-perspective-stock-slips-after-radiopharma-data
Perspective Therapeutics (CATX) stock plunges 22% as Phase 1/2a trial results for VMT-α-NET radiopharmaceutical therapy disappoint investors
https://seekingalpha.com/news/4316690-perspective-stock-slips-after-radiopharma-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.